Eun-Sang Moon(Chairman, President, and CEO) Myung-Suk Song(CFO), Hyun-Pil Shin(Chief Strategy Officer) SillaJen, Biotherapeutics: Helena H. Chaye(CBO), Georg Roth (COO), SillaJen, Inc. is a South Korea-based biotechnology company, with offices in Busan, Yangsan and Seoul, South Korea, and San Francisco, California.
SillaJen began a Phase 3 clinical trial of Pexa-Vec in advanced liver cancer.
In January 2016, SillaJen announces first patient randomized in its global Phase 3 trial for Pexa-Vec in Advanced Liver Cancer.
[17] In July 2017, SillaJen received approval from the China CFDA to commence phase 3 clinical trial for Pexa-Vec in liver cancer.
[18] In Aug 2017, SillaJen signs a cooperative research and development agreement (CRADA or CRDA) with the National Cancer Institute to conduct a clinical study in combination with Pexa-Vec and AstraZeneca's checkpoint inhibitors durvalumab and tremelimumab.